Table 1 Comparison of baseline characteristics between the high- and low-CXI groups
From: Clinical significance of the cachexia index in patients with small cell lung cancer
Characteristic | LD | ED | ||||
|---|---|---|---|---|---|---|
High-CXI group (n = 83) | Low-CXI group (n = 24) | p | High-CXI group (n = 123) | Low-CXI group (n = 37) | p | |
Age | Â | Â | 0.067 | Â | Â | 0.214 |
  < 70 years | 52 (62.7%) | 10 (41.7%) |  | 69 (56.1%) | 25 (67.6%) |  |
  ≥ 70 years | 31 (37.4%) | 14 (58.3%) |  | 54 (43.9%) | 12 (32.4%) |  |
 Median (IQR), years | 66 (61–71) | 70.5 (66–76.5) | 0.033 | 68 (61–74) | 68 (64–71) | 0.754 |
ECOG PS | Â | Â | 0.008 | Â | Â | 0.013 |
 0–1 | 74 (89.2%) | 16 (66.7%) |  | 98 (79.7%) | 22 (59.5%) |  |
 2–3 | 9 (10.8%) | 8 (33.3%) |  | 25 (20.3%) | 15 (40.5%) |  |
Smoking status |  |  | 0.400 |  |  | >  0.998 |
 Never-smoker | 1 (1.2%) | 1 (4.2%) |  | 2 (1.6%) | 0 (0.0%) |  |
 Current/former smoker | 82 (98.8%) | 23 (95.8%) |  | 121 (98.4%) | 37 (100.0%) |  |
Regimen | Â | Â | 0.224 | Â | Â | 0.242 |
 Etoposide and platinum | 83 (100.0%) | 23 (95.8%) |  | 114 (92.7%) | 32 (86.5%) |  |
 Irinotecan and cisplatin | 0 (0.0%) | 1 (4.2%) |  | 9 (7.3%) | 5 (13.5%) |  |
Prophylactic cranial irradiation | Â | Â | 0.132 | Â | Â | 0.006 |
 Yes | 49 (59.0%) | 10 (41.7%) |  | 50 (40.7%) | 6 (16.2%) |  |
 No | 34 (41.0%) | 14 (58.3%) |  | 73 (59.4%) | 31 (83.8%) |  |
Lactate dehydrogenase status (n = 72 in LD, n = 133 in ED) |  |  | 0.339 |  |  | 0.474 |
 Normal | 31 (57.4%) | 8 (44.4%) |  | 34 (34.0%) | 9 (27.3%) |  |
 Elevated | 23 (42.6%) | 10 (55.6%) |  | 66 (66.0%) | 24 (72.7%) |  |
Median BMI (IQR), kg/m2 | 23.0 (20.8–25.2) | 21.9 (20.1–23.8) | 0.104 | 22.6 (20.7–24.5) | 21.0 (19.9–22.5) | 0.007 |